Literature DB >> 12405524

Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale.

Douglas S Mennin1, David M Fresco, Richard G Heimberg, Franklin R Schneier, Sharon O Davies, Michael R Liebowitz.   

Abstract

OBJECTIVE: We sought to determine optimal cutoff values for the Liebowitz Social Anxiety Scale (LSAS) total and subscale scores for the diagnosis of social anxiety disorder (SAD) and designation of the generalized subtype of SAD.
METHOD: Three hundred and sixty-four patients from a multi-site sample who met criteria for SAD according to structured diagnostic interview, 262 of whom met criteria for the generalized subtype, and 34 control participants free of current Axis I disorders participated in this study. All participants were given the Liebowitz Social Anxiety Scale by an independent assessor.
RESULTS: Receiver Operating Characteristics analysis revealed that the LSAS performed well in identifying individuals who met criteria for SAD and for the generalized subtype of SAD. Cutoffs of 30 for SAD and 60 for its generalized subtype on the LSAS total score represented the best balance of specificity and sensitivity.
CONCLUSIONS: These findings provide support for the use of the Liebowitz Social Anxiety Scale for the identification of individuals with SAD and its generalized subtype in clinical settings. Identification of patients with SAD should increase the percentage of these patients who receive appropriate treatment for this impairing disorder.

Entities:  

Mesh:

Year:  2002        PMID: 12405524     DOI: 10.1016/s0887-6185(02)00134-2

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  108 in total

1.  A neuromarker of clinical outcome in attention bias modification therapy for social anxiety disorder.

Authors:  Gal Arad; Rany Abend; Daniel S Pine; Yair Bar-Haim
Journal:  Depress Anxiety       Date:  2018-11-08       Impact factor: 6.505

2.  Cerebellar Neural Circuits Involving Executive Control Network Predict Response to Group Cognitive Behavior Therapy in Social Anxiety Disorder.

Authors:  Yajing Meng; Yan Zhang; Xiaojing Nie; Zhengjia Ren; Hongru Zhu; Yuchen Li; Su Lui; Qiyong Gong; Changjian Qiu; Wei Zhang
Journal:  Cerebellum       Date:  2017-06       Impact factor: 3.847

3.  Linear association between social anxiety symptoms and neural activations to angry faces: from subclinical to clinical levels.

Authors:  Arnaud Carré; Fabien Gierski; Cédric Lemogne; Eric Tran; Delphine Raucher-Chéné; Céline Béra-Potelle; Christophe Portefaix; Arthur Kaladjian; Laurent Pierot; Chrystel Besche-Richard; Frédéric Limosin
Journal:  Soc Cogn Affect Neurosci       Date:  2013-05-07       Impact factor: 3.436

4.  Affect, interpersonal behaviour and interpersonal perception during open-label, uncontrolled paroxetine treatment of people with social anxiety disorder: a pilot study.

Authors:  Lance M Rappaport; Jennifer J Russell; Donald Hedeker; Gilbert Pinard; Pierre Bleau; Debbie S Moskowitz
Journal:  J Psychiatry Neurosci       Date:  2018-08-29       Impact factor: 6.186

5.  Association between attention bias to threat and anxiety symptoms in children and adolescents.

Authors:  Rany Abend; Leone de Voogd; Elske Salemink; Reinout W Wiers; Koraly Pérez-Edgar; Amanda Fitzgerald; Lauren K White; Giovanni A Salum; Jie He; Wendy K Silverman; Jeremy W Pettit; Daniel S Pine; Yair Bar-Haim
Journal:  Depress Anxiety       Date:  2017-12-06       Impact factor: 6.505

6.  Neural correlates of anticipation and processing of performance feedback in social anxiety.

Authors:  Carina Y Heitmann; Jutta Peterburs; Martin Mothes-Lasch; Marlit C Hallfarth; Stephanie Böhme; Wolfgang H R Miltner; Thomas Straube
Journal:  Hum Brain Mapp       Date:  2014-08-05       Impact factor: 5.038

7.  Agenesis of the corpus callosum and autism: a comprehensive comparison.

Authors:  Lynn K Paul; Christina Corsello; Daniel P Kennedy; Ralph Adolphs
Journal:  Brain       Date:  2014-04-25       Impact factor: 13.501

8.  Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

Authors:  Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2020-03-20       Impact factor: 4.905

9.  The Effects of Approach-Avoidance Modification on Social Anxiety Disorder: A Pilot Study.

Authors:  Anu Asnaani; Mike Rinck; Eni Becker; Stefan G Hofmann
Journal:  Cognit Ther Res       Date:  2014-04-01

10.  Treating individuals with social anxiety disorder and at-risk drinking: phasing in a brief alcohol intervention following paroxetine.

Authors:  Sarah W Book; Suzanne E Thomas; Joshua P Smith; Patrick K Randall; Matt G Kushner; Gail A Bernstein; Sheila M Specker; Peter M Miller; Carrie L Randall
Journal:  J Anxiety Disord       Date:  2013-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.